DIFFERENTIAL PATHWAY DEPENDENCY DISCOVERY ASSOCIATED WITH DRUG RESPONSE ACROSS CANCER CELL LINES

Gil Speyer1, Divya Mahendra, Hai J Tran

  • 1The Translational Genomics Research Institute, Phoenix, AZ 85004, U.S.A., gspeyer@tgen.org.

Insights

This study analyzes cancer cell line gene expression and drug response data to find key gene pathways driving drug sensitivity. The findings identify potential drug targets and mediators for personalized cancer treatments.

Area of Science:

  • Genomics
  • Computational Biology
  • Pharmacology

Background:

  • Personalized cancer treatment requires identifying effective drugs with minimal adverse reactions.
  • Understanding gene-drug interactions is crucial for tailoring therapies.

Purpose of the Study:

  • To identify gene pathways with differential dependency in cancer cell lines sensitive or non-sensitive to drugs.
  • To discover mediators of drug response for personalized medicine.

Main Methods:

  • Analysis of gene-expression profiles from 810 cancer cell lines and response data to 368 small molecules from the Cancer Therapeutics Research Portal (CTRP).
  • Utilized the Evaluation of Differential DependencY (EDDY) method to construct gene-dependency networks and assess pathway rewiring.
  • Permutation tests were used to determine the statistical significance of differential gene dependency.

Main Results:

  • Identified 8,811 statistically significant pathways and 26,822 compound-pathway-mediator triplets.
  • Constructed evidence networks for 14,415 triplets using STITCH and STRING databases.
  • Discovered potential mediators influencing cell line sensitivity or resistance to specific drugs.

Conclusions:

  • The study provides a valuable resource for understanding molecular mechanisms of drug response in cancer.
  • Findings can aid researchers in designing personalized treatment regimens and discovering novel drug dependencies.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
57
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
81
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
12.5K